BioSpace News Archive

Seqirus Flu Vaccine Reduces Hospitalization in Retirement Home Patients, Study Shows

Seqirus released new data that shows Fluad, an adjuvanted trivalent influenza vaccine, was more effective than standard non-adjuvanted trivalent influenza vaccine in reducing the risk of flu- and pneumonia-related hospitalization in patients 65-years-of-age and older.

December 9, 2019
·
2 min read
·
Alex Keown
Drug Development

KalVista’s Eye Drug for Diabetic Macular Edema Flunks Mid-Stage Trial

The primary efficacy endpoint was change in best corrected visual acuity (BCVA) at 16 weeks compared to sham (placebo) treatment.

December 9, 2019
·
2 min read
·
Mark Terry
Business

Scilligence and Certara Partner to Improve Client’s Data Analysis and Visualization

Scilligence, an innovation leader of unified informatics platform for biologics and small molecules drug R&D, has partnered with Certara to enable advanced data analysis and visualization capabilities.

December 9, 2019
·
2 min read
Genetown

BC Platforms Partners with leading European Genomics Service Provider Life & Brain to Expand Genotyping Services Across Europe

BC Platforms announced that it has formed a partnership with Life &Brain Genomics, a division of Life & Brain GmbH.

December 9, 2019
·
4 min read
Drug Development

Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Alector, Inc., a clinical stage biotechnology company pioneering immuno-neurology, reported safety and biomarker data from the single ascending dose phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers.

December 9, 2019
·
6 min read
Cancer research offers more hope than people think

Only 28 per cent of people believe cancers can be controlled long term – yet the average patient now lives more than 10 years from diagnosis

December 9, 2019
·
9 min read
Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019

New service reduces the risk, expenditure and time required for the later stages of antibody development

December 9, 2019
·
2 min read
Deals

Merck Snaps Up ArQule and Its BTK Cancer Drug in $2.7 Billion Deal

Merck snapped up the company to gain ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase inhibitor currently in a Phase II dose-expansion study for the treatment of B-cell malignancies.

December 9, 2019
·
2 min read
·
Alex Keown
BioCapital

The 12 Days of Christmas, Biopharma Style

To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.

December 9, 2019
·
8 min read
·
Mark Terry and Alex Keown
Business

Genetown Professionals Weigh In on Ideal Employers

Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.

December 9, 2019
·
5 min read
·
Alex Keown